

## Rates: Collateral damage

Despite ongoing Covid angst, steeper yield curves led by higher long rates gel with a positive vibe for the future. The vaccine helps enormously but big issues remain. Large negative real rates remain indicative of macro stress, and they have moved even deeper negative of late. We still look for higher market rates in 2021, helped by a reflation theme



The Fearless Girl statue in New York's financial district

### The short term outlook: (Un)Lucky dip

We kick off 2021 with market rates still exceptionally low. The German 10yr at -50bp is only marginally above the -70bp hit when Covid first struck. Even the US 10yr is struggled to really break to the upside, although has since finally broken above 1%. While an unconstrained Biden administration will push up the deficit meaning more supply, the near term macro angst will contain the extent to which US market rates can rise.

The macro data in the coming few months will be bad, clearly marking out a double-dip. That's always been a risk case scenario and it is now the central case. The risk case now centres on a longer dip, or something more sinister than a dip.

## The vaccine effect: Good, but big issues remain

The vaccine certainly helps to frame a better medium-term outlook, but other collateral damage left in the wake of the coronavirus impact needs addressing too. Market rates are still below current low inflation rates, which is far from natural as it means we live with negative real rates. Those negative rates paint a very dour picture of the future. In Germany, the 10yr real rate is at -1.5%. In the US it is closer to -1%; higher, but still depressingly low.

But at the same time, implied inflation expectations coming from the difference between conventional and real yields have risen. In the US the implied inflation expectation is now running at over 2% in the 10yr, while in Germany it is just below 1%. The problem is, elevated inflation expectations are partly down to depressed real yields, and that's far from ideal. We are still far from normal market rates.

## The strength of the recovery: The negative real rates conundrum

These are far from certain times, and negative real rates are the clearest measure of the extent of Covid-inspired collateral damage. At the same time (and to cling to positives), negative real rates are highly stimulative and should aid recovery.

The steepening seen in the US yield curve in the past couple of quarters is illustrative of a growing reflationary discount. We are not there yet, but once we get clarity that the dip being experienced is indeed just that, a short dip, there is the underpinning for the US 10yr to stay above 1%. In fact, the profile through 2021 pictures a 25bp ratchet higher in the 10yr in each quarter; not quite getting to 2%, but getting above 1.5% is on the cards.

### Author

**Padhraic Garvey, CFA**

Regional Head of Research, Americas

[padhraic.garvey@ing.com](mailto:padhraic.garvey@ing.com)

### Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies)*. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by

the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.